trial

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

NCTId NCT02505477
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 51 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2023-01-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
51 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2017-02-06
Primary completion
2023-01-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
N-acetylcysteine

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Yvonne Yang, MD, PhDPrincipal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
51
Phase
PHASE4
Primary Completion Date
2023-01-31
Status
COMPLETED
relationships
The graph out of here
drug
N-acetylcysteine
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizophrenia
indication
Schizophrenia; Negative Type
indication
investigator
Yvonne Yang, MD, PhD
person